The US FDA has approved the Roche cobas HPV test for use on next generation cobas 5800 molecular instruments. This approval increases access to HPV testing in mid-size and smaller labs to help enable timely diagnosis of patients who are at risk of developing cervical cancer. With the addition of HPV testing, the cobas 5800 supports critical molecular testing needs with a portfolio of infectious disease, sexual health, respiratory and transplant solutions.

• Roche Diagnostics